Alfabloqueantes: efectos en la mejora de la disfunción eréctil y el deseo sexual en pacientes con hipertrofia prostática benigna

Adequate selection of patients who may benefit from treatment with alpha-blocker, explanation of their benefits and side effects will not only improved lower urinary tract symptoms, but also erectile dysfunction scores. In this case, the most uroselective alpha-blocker silodosin has shown excellent results in both fields, both when administered as monotherapy or associated with PDE5 inhibitors. Furthermore, use of silodosin improved sexual desire parameter as opposed to use of 5 alpha reductase inhibitors.